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Infantile myofibromatosis (IM) is a disorder of mesenchymal proliferation characterized by the development of nonmetastasizing
tumors in the skin, muscle, bone, and viscera. Occurrence within families across multiple generations is suggestive of an autosomal-
dominant (AD) inheritance pattern, but autosomal-recessive (AR) modes of inheritance have also been proposed. We performed
whole-exome sequencing (WES) in members of nine unrelated families clinically diagnosed with AD IM to identify the genetic origin
of the disorder. In eight of the families, we identified one of two disease-causing mutations, c.1978C>A (p.Pro660Thr) and
c.1681C>T (p.Arg561Cys), in PDGFRB. Intriguingly, one family did not have either of these PDGFRBmutations but all affected individ-
uals had a c.4556T>C (p.Leu1519Pro) mutation in NOTCH3. Our studies suggest that mutations in PDGFRB are a cause of IM and high-
light NOTCH3 as a candidate gene. Further studies of the crosstalk between PDGFRB andNOTCH pathways may offer new opportunities
to identify mutations in other genes that result in IM and is a necessary first step toward understanding the mechanisms of both tumor
growth and regression and its targeted treatment.Infantile myofibromatosis (IM [MIM 228550]) is one of the
most common proliferative fibrous tumors of infancy and
childhood. First described by Williams and Schrum1 and
Stout,2 IM was further subcategorized by others into soli-
tary, multiple, or generalized forms and shown to affect
the skin, muscle, bone, and viscera.3,4 The term ‘‘infantile
myofibromatosis’’ was recommended based on the fact
that the cells have features of both differentiated fibro-
blasts and smooth muscle cells (myofibroblasts).5 Soft tis-
sue lesions usually arise during childhood but can arise at
any time during life and, intriguingly, can regress sponta-
neously. On the other hand, visceral lesions are associated
with high morbidity and mortality.6 The mechanism(s)
underlying tumor growth and regression are not known.
Some have suggested tumor growth to be linked to angio-
genic stimulation and regression.7 Indeed, in a single case
report, regression of an intracardiac IM was achieved
through use of interferon alpha-2b.8
The genetic etiology of IM is unknown and both auto-
somal-recessive (AR) and autosomal-dominant (AD) pat-
terns of inheritance have been reported. Consanguinity
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The Americaccord with an AR pattern of inheritance.9–11 A large num-
ber of pedigrees, wherein affected individuals are identified
across generations, are consistent with IM being an AD
disease.12–19
After informed consent and Institutional Review Board
approval from the Icahn School of Medicine of Mount
Sinai and the corresponding institutions were obtained,
blood samples were obtained from 32 affected individuals
from 9 unrelated families with the diagnosis of IM and,
where possible, unaffected family members (Figure 1).
Clinical diagnoses were provided by the referring physi-
cians. Genomic DNA was extracted with the Puregene
kit according to the manufacturer’s protocol. Cell lines
were established from tumor tissue that was removed
from affected individuals as part of their medical care
and which was considered pathologic waste. One unaf-
fected and 11 affected family members, representing 9
unrelated kindreds, were selected for whole-exome
sequencing at the Center for Applied Genomics at The
Children’s Hospital of Philadelphia. Genomic DNA was
isolated from a blood sample by standard methods and
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Figure 1. Pedigrees of Nine Unrelated IM Families
The inheritance pattern in all the families used in this study was consistent with autosomal-dominant transmission. Five families have
been previously reported: IM-1,14 IM-2,15 IM-6,14 IM-7,16 IM-8.17 Asterisk indicates that these samples were whole-exome sequenced.
1002 The American Journal of Human Genetics 92, 1001–1007, June 6, 2013
Figure 2. Mutations in PDGFRB and
NOTCH3
(A) Representative sequence chromato-
grams for each of the different mutations
identified.
(B) Conservation of the mutations and the
surrounding region in vertebrates. Arrows
indicate the positions of the mutated
alleles.end-repair, A-tailing, and paired-end index adaptor
ligation. Whole exomes were captured with the Agilent
SureSelect Human All Exon V4þUTR kit (Agilent Technol-
ogies) according to the manufacturer’s protocol. The
libraries were subsequently clustered on the cBOT instru-
ment, multiplexing 4 samples per flow cell lane, and
sequenced for 101 cycles with a paired-end mode on the
Illumina HiSeq2000 according to the manufacturer’s
instructions (Illumina). Base calling and index demulti-
plexing was performed with the Illumina CASAVA soft-
ware (v.1.8.2).
Sequencing reads were aligned to the human reference
genome (UCSC hg19) with Burrows-Wheeler Aligner
(BWA, v.0.6.2).20 Optical and PCR duplicates were marked
and removed with Picard (v.1.73). Local realignment of
reads containing indel sites and base quality score recalibra-
tion (BQSR)wereperformedwith theGenomeAnalysis Tool
Kit (GATK, v.2.3).21 Single-nucleotide variation (SNV) and
small indels were called with GATK UnifiedGenotyper.
Variants were marked as potential sequencing artifacts if
the filters on the following annotations were evaluated
to be true: (1) for SNVs, DP < 10, QD < 2.0, MQ <
40.0, FS > 60.0, HaplotypeScore > 13.0, MQRankSum <
12.5, ReadPosRankSum < 8.0; and (2) for small
indels, DP < 10, QD < 2.0, ReadPosRankSum < 20.0,
InbreedingCoeff < 0.8, FS > 200.0. The kinship coeffi-
cient was calculated for each sample via KING22
to confirm reported relationships and identify cryptic
relationships among samples. ANNOVAR23 and SnpEff
(v.2.0.5)24 were used for annotating variants. Human
Gene Mutation Database (HGMD)25 was used for anno-
tating known genes and mutations for human inherited
diseases. Prediction scores from SIFT,26 Polyphen2,27
LRT,28 and MutationTaster,29 along with conservation
scores PhyloP30 and GERPþþ,31 for every potential nonsy-
nonymous SNV in the human genome were retrieved
from dbNSFP (database for nonsynonymous SNPs’ func-
tional predictions).32 SNVs and indels were selected as
potential pathogenic variants if they met all the following
criteria: (1) heterozygous; (2) not previously described or
rare (minor allele frequency [MAF] < 0.5%) in a control
cohort of more than 9,000 control individuals (1000The American Journal of Human GGenomes Project, April 2012 release),
6,503 exomes fromNHLBI GO Exome
Sequencing Project (ESP6500SI), and
1,200 in-house whole exomes; (3)
nonsynonymous, or splice acceptorand donor site SNVs, or frameshift coding indels (NS/
SS/I); (4) predicted to be deleterious by at least three predic-
tion methods, e.g., SIFT, PolyPhen2, MutationTaster, and
LRT; and (5) conserved PhyloP score and GERPþþ score >
2.0. Variants were also analyzed by the Ingenuity Variant
Analysis web-based application.
On average, 9.7 Gb of sequences were produced for each
sample, 97% of the reads were mappable to the human
reference genome (hg19), and 94% of targeted exome
had at least 103 depth of coverage. The mean depth of
coverage was 74-fold. A total of 195,651 SNVs and
20,700 indels were identified, of which 178,991 SNVs
(91%) and 17,238 indels (83%) were reported in
dbSNP135. On average, 82,855 SNVs and 11,882 indels
were called per sample. We applied the filtering strategy
to focus on a subset of potentially pathogenic variants.33
Variants were filtered bymode of inheritance, variant qual-
ity, conservation, predicted deleterious scores, and allele
frequency in the public and in-house whole exomes.
Two missense variants in PDGFRB (MIM 173410; RefSeq
accession number NM_002609.3) were present in eight
members in eight families. No PDGFRB mutations were
identified in family IM-9 (Table S1 available online).
Sanger sequencing of all available family members,
affected and unaffected, in the eight families revealed
that the two PDGFRB variants segregated appropriately
with disease status (Figure 2). In family IM-9, in which
no PDGFRB mutations were identified, we exome
sequenced two other affected and one unaffected individ-
ual from this kindred. Variants in NOTCH3 (MIM 600276;
NM_000435.2) and PET112 (MIM 603645; NM_004564.2)
were found in all three affected members but not in the
unaffected family member (Table 1). Sanger sequencing
of 16 family members, consisting of 9 affected and 7 unaf-
fected individuals, revealed that only the NOTCH3 muta-
tion c.4556T>C (p.Leu1519Pro) segregated appropriately
with affected status (Figure 2). Given the unexpected
finding of candidate disease-causing mutations in a second
gene, we re-examined the histologic findings in a soft tis-
sue tumor isolated from this family and also generated a
cell line from affected tissue.34 Histopathologic analysis
was consistent with the diagnosis of IM, and stainingenetics 92, 1001–1007, June 6, 2013 1003
Table 1. Rare Variants in PDGFRB and NOTCH3 Identified in Nine IM Families from WES
Gene (MIM)
Genomic Location
(hg19) (RefSeq) Exon Family cDNA Protein
MAF in 1000 Genomes
Project or ESP6500SI
PDGFRB (173410) chr5: 149,503,858
(NM_002609.3)
14 IM-1 c.1978C>A Pro660Thr 0.000077
PDGFRB (173410) chr5: 149,505,134
(NM_002609.3)
12 IM-2–IM-8 c.1681C>T Arg561Cys –
NOTCH3 (600276) chr19: 15,285,059
(NM_000435.2)
25 IM-9 c.4556T>C Leu1519Pro –with a-SMA further demonstrated the tumor’s myofibro-
blastic nature (Figure 3).
All three rare missense variants in both genes were pre-
dicted to be damaging with high probability according
to the prediction algorithms LRT, MutationTaster,
Polyphen2, and SIFT and they were located in highly
conserved exonic regions. In PDGFRB, we identified a
heterozygous missense variant in exon 14, c.1978C>A
(p.Pro660Thr). It is located in the tyrosine kinase domain
of the protein. Interestingly, the variant was present in
the ESP6500SI data set with a MAF of 0.000077. It was
reported in dbSNP135 (rs144050370) but was not found
in the 1000 Genomes Project, in the catalog of somatic
mutations in cancer (COSMIC v.63), nor in a database of
approximately 1,200 in-house sequenced whole exomes.
The second PDGFRB variant is a heterozygous missense
variant in exon 12, c.1681C>T (p.Arg561Cys). It is not pre-
sent in the publically available databases nor in approxi-
mately 9,000 public and in-house sequenced whole-exome
data sets. For family IM-9, the NOTCH3 variant c.4556T>C
(p.Leu1519Pro) predicts a heterozygous missense variant
in exon 25. It is a newly described variant, not present in
public databases and in-house whole exomes. It is located
in the protein’s highly conserved hetero-dimerization
domain.
In our current study, twomissense mutations in PDGFRB
were identified in eight IM families. PDGFRB, located on
5q32, encodes the platelet-derived growth factor recep-
tor-b. It is a cell surface tyrosine kinase receptor for mem-
bers of the platelet-derived growth factor family (PDGF A,
B, C, and D), which are mitogens for cells of mesenchymal
origin. Activation of the receptor leads to its dimerization,
autophosphorylation of tyrosine residues, and activation
of downstream signaling pathways, inducing cellular
proliferation, differentiation, survival, and migration.
PDGFRB is expressed in neurons, plexus choroideus,
vascular smooth muscle cells (VSMCs), and pericytes.
PDGFRB signal transduction is required for proliferation
and migration of a subset of VSMCs. PDGFRB signaling
has been well established in early hematopoiesis and blood
vessel formation.35 Enhanced PDGF-PDGFR signaling is a
hallmark in a variety of diseases, including cancers, athero-
sclerosis, pulmonary fibrosis, and restenosis. Recently, a
missense mutation, c.1973T>C (p.Leu658Pro) in PDGFRB,
was reported to be an identified cause of idiopathic basal
ganglia calcification (IBGC [MIM 615007]).361004 The American Journal of Human Genetics 92, 1001–1007, JuneOnenovelmissensemutation, c.4556T>C (Leu1519Pro),
in NOTCH3 was identified as the most probable causa-
tive mutation for one IM family. NOTCH3 encodes
the third discovered human homolog of the Drosophila
melanogaster type I membrane protein notch. Notch
signaling allows cells to coordinate fate decisions in
metazoan development. Notch signals are highly
pleiotropic, dictating cellular fates in a way that depends
on cellular context. NOTCH3 is primarily expressed in
adult arterial vascular smooth muscle cells (VSMCs) in
large conduit, pulmonary, and systemic resistance
arteries. Mutations in NOTCH3 have also been identi-
fied as the underlying cause of cerebral autosomal-
dominant arteriopathy with subcortical infarcts and
leukoencephalopathy (CADASIL [MIM 125310]).37 The
NOTCH3 IM family members are notable for possess-
ing multiple, recurrent soft tissue lesions and have no
reported clinical history consistent with a diagnosis of
CADASIL. The majority of reported CADASIL-associated
mutations affect amino acids that are located in the
epidermal growth factor-like (EGF-like) domain in the
extracellular domain of the protein (exons 2–24).
Recently, Fouillade et al. reported a heterozygous
missense mutation (c.4544T>C [p.Leu1515Pro]) in
exon 25, a highly conserved hetero-dimerization domain
of Notch3, in an affected individual with cerebral
small vessel disease but lacking typical deposits and
Notch3 accumulation.38 Biochemical analysis suggests
that the c.4544T>C (p.Leu1515Pro) mutation renders
Notch3 hyperactive through destabilization of the hetero-
dimer. Themutation c.4556T>C (p.Leu1519Pro) identified
in an IM family was located close to the Leu1515Pro
substitution.
Of particular interest, in trying to understand howmuta-
tions in two different genes, PDGFRB and NOTCH3, could
result in the same disease, a possible mechanistic link was
recently provided. Specifically, Jin et al. demonstrated that
PDGFRB was a previously unrecognized and immediate
NOTCH3 target gene.39 PDGFRB expression was upregu-
lated by NOTCH3 ligand induction or by activated forms
of the NOTCH3 receptor. The availability of established
tumor cell lines from affected individuals will allow us to
directly explore this mechanistic link. Importantly, if these
two signaling pathways are linked and the IM disease-
causing mutations in either PDGFRB or NOTCH3 are
demonstrated to be activating, theoretically, inhibition of6, 2013
Figure 3. Tumor Cell Lines Derived from
Affected Individuals Demonstrate a
Myofibroblastic Phenotype
Vimentin (green) and a-SMA (red) staining
of tumor cell lines from members of family
IM-9. Cells were cultured from a soft-tissue
tumor excised from an affected area on the
affected individual’s back as part of their
care. Three paired views at 203 (left col-
umn) and 403 (right column) are shown.PDGFRB or NOTCH3 would result in a targeted therapeutic
strategy.
In conclusion, our study suggests that PDGFRB muta-
tions are a cause of autosomal-dominant IM, a genetically
heterogeneous disease with incomplete penetrance and
variable expressivity. These studies have also identified a
single family with a germline NOTCH3 mutation. Study
of the PDGFRB/NOTCH3 pathways will offer new opportu-
nities to identify other IM mutations and/or genes and to
understand the mechanisms of both tumor growth and
regression in IM.Supplemental Data
Supplemental Data include one table and can be found with this
article online at http://www.cell.com/AJHG/.Acknowledgments
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